Editorial: Exploring Cutaneous Drug-Related and Drug-Associated Adverse events: from Clinical Insights to Therapeutic Management

1

Pembrolizumab and dupilumab have shown efficacy in treating adverse cutaneous reactions in cancer patients, highlighting the need for tailored therapies.
2

JAK inhibitors are associated with cutaneous side effects and infections, necessitating careful monitoring and further investigation in real-world settings.
3

Topical steroids remain a mainstay treatment for various skin conditions, but their misuse can lead to significant adverse effects like iatrogenic Cushing syndrome.
4

The complexity of cutaneous adverse events from immunotherapies underscores the importance of multidisciplinary management in oncological care.
5

Integrating pharmacovigilance with clinical data is crucial for enhancing patient safety and optimizing treatment outcomes in drug-related skin reactions.

1